HENDERSON, Nev.--(BUSINESS WIRE)--3PEA International, Inc. (OTCBB:TPNL)(OTCQB:TPNL), a vertically integrated provider of innovative prepaid card programs and processing services for corporate, consumer and government applications, today announced that 3PEA and Haemonetics Corporation (NYSE:HAE) have entered into an agreement whereby 3PEA International will integrate its PaySign® Connect prepaid debit card solution with Haemonetics’ Donor Management System (“DMS”). The integration will allow users of the Haemonetics DMS to use the PaySign Connect payment solution for the plasma industry. This partnership will bring together the best of both worlds, the industry leading Haemonetics Donor Management System and 3PEA’s PaySign® Connect, an intuitive, easy-to-use, fully tokenized payment system tailored to the unique requirements of the plasma collection industry.
“We are excited to partner with Haemonetics to integrate The PaySign Connect payment solution with their Donor Management System,” explained Mark Newcomer, Chairman and CEO, 3PEA International. “We are confident that the combination of Haemonetics’ DMS and the PaySign Connect payment solution will be welcomed by the industry as the solution of choice for their donor payment and management needs.”
“We are continually striving to improve and expand our offerings to our plasma customers.” commented Pete Allen, President, Global Plasma for Haemonetics. Tony Joy, Director, Plasma Software Sales, added “Working with 3PEA to integrate its PaySign® Connect prepaid debit card solution with Haemonetics’ DMS is another example of providing options that enable our customers to further improve the efficiencies of their operations. We’re looking forward to a successful relationship with 3PEA as they increase their presence in the plasma donation payments space.”
About 3PEA International
3PEA International (OTCBB:TPNL) is an experienced and trusted prepaid debit card payment solutions provider as well as an integrated payment processor that has millions of prepaid debit cards in its portfolio. Through its PaySign brand, 3PEA designs and develops payment solutions, prepaid card programs, and customized payment services. 3PEA manages programs for many of the world’s largest pharmaceutical manufacturers with copay assistance products designed to maximize new patient acquisition, retention and adherence. 3PEA’s corporate incentive prepaid cards are changing the way corporations reward, motivate and engage their current and potential customers, employees and agents. 3PEA’s customizable prepaid solutions offer significant cost savings while improving brand recognition and customer loyalty. 3PEA’s customers include healthcare companies, major pharmaceutical companies and source plasma providers, large multinationals, prestigious universities and social media companies. PaySign is a registered trademark of 3PEA Technologies, Inc. in the United States and other countries. For more information visit us at www.3pea.com or follow us on LinkedIn, Twitter and Facebook.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. 3PEA undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.